Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells

  • Hou, Zhi-Hong (Pharmacy Department, The 208th Hospital of PLA) ;
  • Zhao, Wen-Cui (Pharmacy Department, The 208th Hospital of PLA) ;
  • Zhang, Qi (Pharmacy Department, The 208th Hospital of PLA) ;
  • Zheng, Wei (Medical Department, The 208th Hospital of PLA)
  • Published : 2015.03.18


Objective: To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 cells. Materials and Methods: The viability of HepG2 cells was assessed using MTT under different concentrations of prepared paclitaxel-loaded particles and paclitaxel (6.25, 12.5, 25, 50, and 100 mg/L), and apoptosis was analyzed using Hochest33342/Annexin V-FITC/PI combined with an IN Cell Analyzer 2000. Results: Paxlitaxel-loaded nanoparticles were characterized by narrow particle size distribution (158.6 nm average particle size). The survival rate of HepG2 cells exposed to paclitaxel-loaded PLGA particles decreased with the increase of concentration and time period (P<0.01 or P<0.05), the dose- and time-dependence indicating sustained release (P<0.05). Moreover, apoptosis of HepG2 cells was induced, again with an obvious dose- and time-effect relationship (P<0.05). Conclusions: Paclitaxel-loaded PLGA particles can inhibit the proliferation and induce the apoptosis of HCC HepG2 cells. This new-type of paclitaxel carrier body is easily made and has low cost, good nanoparticle characterization and sustained release. Hence, paclitaxel-loaded PLGA particles deserve to be widely popularized in the clinic.


Paclitaxel-loaded nanoparticles;HCC;HepG2 cells;viability;apoptosis


  1. Chao G, Fan L, Jia W, et al (2007). Synthesis, characterization and hydrolytic degradation of degrable poly (butylenes terephthalate)/poly (ethlene glycol) (PBT/PEG) copolymers. J Mater Sci Mater Med, 18, 449-55.
  2. Danhier F, Danhier P, De Saedeleer CJ, et al (2015). Paclitaxelloaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. Int J Pharm, 479, 399-407.
  3. Desai N (2007). Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPAR. Nanomed Nanotechnol Biol Med, 3, 339.
  4. Dong XL, Xu PF, Miao C, et al (2012). Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Biomed Pharmacother, 66, 70-5.
  5. Feng W, Xiaoyan X, Xuan Y, et al (2015). Silencing stathminmodulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel. Cancer Gene Ther, [Epub ahead of print].
  6. Gong C, Shi S, Wu L, et al (2009). Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2: sol-gelsol transition and drug delivery behavior. Acta Biomater, 5, 3358-70.
  7. Jianmin Zou, Gundry S, Ganic E, et al (2014). Mathematical models for absorption and efficacy of ovarian cancer treatments. Conf Proc IEEE Eng Med Biol Soc, 3442-5.
  8. Langer CJ, Hirsh V, Ko A, et al (2015). Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer, 16, 112-20.
  9. Lim SJ, Choi HG, Jeon CK, et al (2015). Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells. Oncol Rep, 33, 2023-30.
  10. Lin Y, Jiang D, Li Y, et al (2015). Effect of sun ginseng potentiation on epirubicin and paclitaxel-induced apoptosis in human cervical cancer cells. J Ginseng Res, 39, 22-8.
  11. Ma GL, Miao BL, Song CX (2010). Thermosensitive PCL-PEGPCL hydrogels: Synthesis, characterization, and delivery of proteins. J Appl Polym Sci, 116, 1985-93.
  12. Qiu D, Zhu H (2009). Advances in research on surface modification of paclitaxel-polylactide nanoparticles. Chem Ind Eng Prog, 28, 1198-201.
  13. Pan Y, Ni HH, Zou AF et al (2013). The research of paclitaxelloaded nanoparticles by human serum albumin as drug delivery vectors. Chin J Antibiot, 28, 853-8.
  14. Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, et al (2013). Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev, 14, 2421-7.
  15. Symmans WF, Volm MD, Shapiro RL, et al (2000). Paclitaxelinduced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res, 6, 4610-7.
  16. Tanaka S, Iwamoto M, Kimura K, et al (2014). Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer, [Epub ahead of print].
  17. Xu M, Takanashi M, Oikawa K, et al (2012). Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen. Cancer Sci, 103, 821-7.
  18. Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu$^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4.
  19. Wang H, Xu LF, Zhang C, et al (2013). Paclitaxel-loaded PLGA/ f69 nanoparticles reverse multidrug resistance in breast cancer cells. Bme and Clin Med, 17, 17-21.
  20. Yadav D, Anwar MF, Garg V, et al (2014). Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac J Cancer Prev, 15, 2335-40.